Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
88°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Clovis Oncology, Inc.
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
December 12, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
September 21, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
September 11, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
August 08, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
July 20, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status
June 06, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
June 14, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
May 05, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
May 04, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
April 28, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
April 20, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
April 08, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
March 31, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
March 16, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
February 25, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
February 23, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
February 10, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
January 10, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
December 09, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces Third Quarter 2021 Operating Results
November 03, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
October 20, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
October 19, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
October 07, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
September 20, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
August 16, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces Second Quarter 2021 Operating Results
August 04, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
July 21, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
July 12, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
June 28, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
June 23, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Tickers
CLVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.